Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

By Robert Chen, P. Zinzani, M. Fanale, P. Armand, N. Johnson, P. Brice, J. Radford, V. Ribrag, D. Molin, T. Vassilakopoulos and 7 more. Journal of Clinical Oncology, 2017

862 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/992a44bfed2f3845c7fa85bde73a3f0e6d6f49d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Hellmann
2. A. Schoenfeld

In Oncology

1. J. Gong
2. S. Reddi
3. Alexander Chehrazi-Raffle
4. Ravi Salgia
5. M. Hellmann
6. A. Schoenfeld

Citations in the corpus

• Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “This showed an overall response rate of 69%—of which, 22% had complete remission and the median duration of response was 11 months [59].”
• Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, background): “On March 15, 2017, pembrolizumab received approval for a hematologic malignancy based on the findings from the KEYNOTE-087 trial (Table 5) [44].”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “…advanced or metastatic NSCLC with PD-L1 positivity [325], metastatic urothelial carcinoma [326], cervical cancer [327], classical Hodgkin lymphoma [328], microsatellite-unstable or mismatch repair-deficient cancer [329], gastric cancer [330] and primary mediastinal large B-cell lymphoma [331],…”
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018, neutral): “Median age, years (IQR) 33 (26-45) 37 (28-48) 32 (25-47) 34 (26-46) $ 60 5 (8) 7 (9) 3 (3) 15 (6) Male 34 (54) 51 (64) 56 (56) 141 (58) ECOG PS 0 39 (62) 42 (53) 50 (50) 131 (54) 1 24 (38) 38 (48) 50 (50) 112 (46) Disease stage at study entry I 1 (2) 1 (1) 2 (2) 4 (2) II 20 (32) 11 (14) 20 (20) 51 (”
• Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “melanoma, Merkel cell, Hodgkin’s lymphoma, MSI high tumors) (Armand et al., 2018; Chen et al., 2017; Hamid et al., 2019; Larkin et al., 2019; Le et al., 2017; Nghiem et al., 2019) while the response rates in most other approved diseases is limited to 10–25% (Antonia et al.”